$144 Million is the total value of TRV GP II, LLC's 3 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVMD | REVOLUTION MEDICINES, INC. | $75,590,000 | +13.8% | 1,909,317 | 0.0% | 52.65% | +22.1% | |
| JNCE | Sell | JOUNCE THERAPEUTICS, INC. | $64,402,000 | -22.9% | 9,200,349 | -10.1% | 44.86% | -17.2% |
| ALNA | ALLENA PHARMACEUTICALS, INC. | $3,572,000 | -13.5% | 2,790,964 | 0.0% | 2.49% | -7.2% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Mark Levin #1
- Kevin P. Starr #2
- Robert I. Tepper #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JOUNCE THERAPEUTICS, INC. | 20 | Q3 2022 | 100.0% |
| ALLENA PHARMACEUTICALS, INC. | 19 | Q2 2022 | 24.4% |
| BLUEPRINT MEDICINES CORPORATION | 6 | Q1 2019 | 47.1% |
| REVOLUTION MEDICINES, INC. | 5 | Q1 2021 | 55.4% |
| SAGE THERAPEUTICS, INC. | 5 | Q4 2018 | 16.3% |
| MYOKARDIA, INC. | 2 | Q1 2018 | 21.9% |
View TRV GP II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-05 |
| 4 | 2021-09-17 |
| 13F-HR | 2021-08-11 |
| 4 | 2021-06-14 |
| 4 | 2021-06-07 |
| 4 | 2021-05-27 |
View TRV GP II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.